WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

• 

• John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci

  Professor of Medical Oncology
  Barts Cancer Institute
  Queen Mary University of London
  London, United Kingdom

  Disclosures

  Disclosure: John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: AbbVie; Acerta; AstraZeneca; Bristol Myers Squibb Company; Celgene; Gilead; Janssen; Kite; Roche; TG Therapeutics
  Served as a speaker or a member of a speakers bureau for: AbbVie; Celgene; Roche
  Received grants for clinical research from: AstraZeneca; Celgene; Janssen

• 

• John P. Leonard, MD

  Professor of Hematology and Medical Oncology
  Weill Cornell Medicine
  New York, New York, United States

  Disclosures

  Disclosure: John P. Leonard, MD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: ADC Therapeutics; AstraZeneca; Bayer; Bristol Myers Squibb Company; Celgene; Epizyme; Genentech; Gilead; Kite; MEI Pharma; Miltenyi; Regeneron; Roche; Sutro
  Received grants for clinical research from: Agios; Celgene; Epizyme; Janssen

• 

• Stefano Luminari, MD

  Associate Professor Medical Oncology
  University of Modena and Reggio Emilia
  Head of the Clinical Research Lymphoma Program of Hematology Unit
  AUSL IRCCS of Reggio Emilia
  Modena, Italy

  Disclosures

  Disclosure: Stefano Luminari, MD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Celgene; iQone; Roche

• 

• Gilles Salles, MD, PhD

  Professor of Medicine at the University Claude Bernard of Lyon
  Chair of the Hematology Department
  Lyon University Hospital
  Lyon, France

  Disclosures

  Disclosure: Gilles Salles, MD, PhD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: AbbVie; Autolus; Celgene; Epizyme; Genmab; Gilead; Janssen; Karyopharm; Kite; Merck; Morphosys; Novartis; Roche; Servier; Takeda

Steering Committee

• Gilles Salles, MD, PhD

  As seen above

• Jeremy S. Abramson, MD

  Associate Professor of Medicine
  Harvard Medical School
  Director, Center for Lymphoma
  Massachusetts General Hospital
  Boston, Massachusetts, United States

  Disclosures

  Disclosure: Jeremy S. Abramson, MD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: AbbVie; Allogene; Celgene; EMD Serono; Karyopharm; Kite; Morphosys; Novartis; Roche
  Received grants for clinical research from: Celgene; Seattle Genetics

• Koji Izutsu, MD, PhD

  Chief, Department of Hematology
  National Cancer Center Hospital
  Tokyo, Japan

  Disclosures

  Disclosure: Koji Izutsu, MD, PhD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: AbbVie; Celgene
  Served as a speaker or a member of a speakers bureau for: AbbVie; AstraZeneca; Bayer; Bristol-Myers Squibb; Chugai; Dainihon Sumitomo; Eisai; HUYA; Janssen; Kyowa Kirin; Merck Sharpe & Dohme; Mundipharma; Ninon Mediphysics; Novartis; Ono; Takeda
  Received grants for clinical research from: AbbVie; AstraZeneca; Bayer; Celgene; Cugai; Daiichi; Incyte; Kyowa Kirin; Pfizer; Sankyo; Solasia; Takeda; Yakult

• Marie Josie Kersten, MD, PhD

  Professor of Hematology
  Amsterdam University Medical Center
  Amsterdam, Netherlands

  Disclosures

  Disclosure: Marie Josie Kersten, MD, PhD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Amgen; Bristol-Myers Squibb; Celgene; Cilag; Gilead; Janssen; Kite; Merck Sharpe & Dohme; Miltenyi Biotech; Novartis; Roche
  Served as a speaker or a member of a speakers bureau for: Celgene; Gilead; Kite; Novartis; Roche
  Received grants for clinical research from: Celgene; Roche; Takeda

• Marion Subklewe, MD

  Professor for Cellular Immunotherapy
  Associate Professor for Hematology
  University Hospital of Munich
  Munich, Germany

  Disclosures

  Disclosure: Marion Subklewe, MD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Amgen; Celgene; Gilead; Novartis; Roche; Seattle Genetics
  Served as a speaker or a member of a speakers bureau for: Amgen; Celgene; Gilead
  Received grants for clinical research from: Amgen; Gilead; Morphosys; Roche

• Umberto Vitolo, MD

  Department of Oncology and Hematology
  University of Turin
  Turin, Italy

  Disclosures

  Disclosure: Umberto Vitolo, MD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Celgene; Gilead; Janssen
  Served as a speaker or a member of a speakers bureau for: AbbVite; Celgene; Gilead; Novartis; Roche

Editors

• Andrew D. Bowser, ELS, CHCP

  Scientific Content Manager

  Disclosures

  Disclosure: Andrew D. Bowser, ELS, CHCP, has disclosed the following relevant financial relationships:
  Spouse served as an advisor or consultant for ALK, CSL Behring, and Pharming
  Spouse served as a speaker for Shire/Takeda

• Sanneke Koekkoek

  Medical Education Director, WebMD Global, LLC

  Disclosures

  Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships.

Content Reviewer

• Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

  Associate Director, Accreditation and Compliance

  Disclosures

  Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BeiGene
Received grants for clinical research from: Gilead Sciences